|
Dr. Barrett is currently a General Partner with the venture capital firm New Enterprise Associates, the lead investor in GMI's seed round of financing. He founded Sensors for Medicine and Science, Inc. in 1997, and serves as Chairman of its board. In 1987, he founded Genetic Therapy, Inc. (GTI) which was sold in August of 1995 to Swiss pharmaceutical giant Sandoz AG (now Novartis) for $300-million. He continued to serve as GTI's CEO and as a Director through June 1996. From 1982 to July of 1987, Dr. Barrett served as President of Life Technologies, Inc. (now part of Invitrogen) and its predecessor, Bethesda Research Laboratories. Prior to 1982, he was employed at SmithKline Beecham Corporation for 13 years, where he held a variety of positions, including President of its In Vitro Diagnostics Division and President of SmithKline Clinical Laboratories. Dr. Barrett was a Director of MedImmune, Inc. from 1988 until its acquisition by AstraZeneca in 2007. | 